文章：

FDA批准肉瘤药物价格与趋势分析

Prices and Trends in FDA-Approved Medications for Sarcomas

原文发布日期：18 April 2024

DOI: 10.3390/cancers16081545

类型: Article

开放获取: 是

英文摘要：

Sarcomas represent a diverse set of both malignant and benign subtypes consisting of often rare and ultra-rare conditions. Over the course of the last decade, there have been numerous FDA approvals for agents treating various sarcoma subtypes. Given this burgeoning landscape of sarcoma treatments, we seek to review current FDA-approved agents with respect to their rates of incidence, approval rates, and financial costs. We gathered clinical trial data by searching FDA approval announcements from 2013 to 2023. We determined the 30 day and one year cost of therapy for patients of FDA-approved sarcoma treatments in the aforementioned timeframe. From 2013 to 2023, 14 medications have been FDA-approved for sarcoma subtypes. The 30-day dosing prices for these medications range from $11,162.86 to $46,926.00. Since 2013, the rates of approval for sarcoma medications have been higher than in prior decades. Nonetheless, there remains the potential for significant financial toxicity for patients living with sarcoma.

摘要翻译： 

肉瘤代表了一组多样化的恶性和良性亚型，通常属于罕见及超罕见疾病。在过去十年间，美国食品药品监督管理局已批准了多种针对不同肉瘤亚型的治疗药物。鉴于肉瘤治疗领域的迅速发展，本文旨在回顾当前FDA批准药物的发病率、批准率及经济成本。我们通过检索2013年至2023年间的FDA批准公告收集了相关临床试验数据，并测算了该时间段内FDA批准的肉瘤治疗方案在30天及一年期内的患者治疗成本。2013年至2023年间，共有14种药物获得FDA批准用于治疗肉瘤亚型。这些药物的30天疗程价格区间为11,162.86至46,926.00美元。自2013年以来，肉瘤药物的批准率较前几十年显著提高。然而，肉瘤患者仍可能面临沉重的经济负担。

原文链接：

Prices and Trends in FDA-Approved Medications for Sarcomas